Phosphodiesterase type 5 inhibitor administered immediately after radical prostatectomy temporarily increases the need for incontinence pads, but improves final continence status. [PDF]
Investig Clin Urol, 2016 Purpose: To evaluate the effects of phosphodiesterase type 5 inhibitor (PDE5i) on urinary continence recovery after bilateral nerve-sparing radical prostatectomy (BNSRP). Materials and Methods: Between 2002 and 2012, 137 of 154 consecutive patients who
Kaiho Y +8 more
europepmc +2 more sources
Changes in peak systolic velocity induced by chronic therapy with phosphodiesterase type-5 inhibitor [PDF]
, 2006 The aim of this study was to assess the influence of chronic therapy with phosphodiesterase type-5 inhibitor on penile haemodynamics at colour Doppler ultrasound.
A. Mofferdin +6 more
core +3 more sources
The Efficacy of Medical Treatment of Peyronie's Disease: Potassium Para-Aminobenzoate Monotherapy vs. Combination Therapy with Tamoxifen, L-Carnitine, and Phosphodiesterase Type 5 Inhibitor. [PDF]
World J Mens Health, 2016 Purpose: This study was designed to evaluate the efficacy of medical treatment of Peyronie’s disease. Materials and Methods: A total of 109 patients with Peyronie’s disease who had been treated from January 2011 to December 2014 were retrospectively ...
Park TY +8 more
europepmc +2 more sources
Sexual Medicine, 2020 Introduction: Cavernositis is a rare acute infection of the corporal bodies of the penis. It might result in corporal cavernosal abscesses, fibrosis, and subsequently erectile dysfunction if the treatment is inadequate.
Abdulaziz Bakhsh, MD, MBA +4 more
doaj +1 more source
BMC Research Notes, 2022 Objective To evaluate the efficacy and safety of add-on therapy with the phosphodiesterase type 5 inhibitor tadalafil in Japanese men with lower urinary tract symptoms (LUTS) due to benign prostatic hyperplasia (BPH) treated with dutasteride.
Daisuke Gotoh +6 more
doaj +1 more source
Sildenafil, a Phosphodiesterase Type 5 Inhibitor, Downregulates Osteopontin in Human Peripheral Blood Mononuclear Cells. [PDF]
Arch Immunol Ther Exp (Warsz), 2017 Kaleta B, Boguska A.
europepmc +3 more sources
Phosphodiesterase Type 5 Inhibitors, Sport and Doping [PDF]
Current Sports Medicine Reports, 2017 Phosphodiesterase type 5 inhibitors (PDE5i) (e.g.,sildenafil, tadalafil, vardenafil, and avanafil) are drugs commonly used to treat erectile dysfunction, pulmonary arterial hypertension, and benign prostatic hyperplasia. PDE5i are not prohibited by the World Anti-Doping Agency (WADA) but are alleged to be frequently misused by healthy athletes to ...
Di Luigi, Luigi +8 more
openaire +4 more sources
Frontiers in Pharmacology, 2023 An evidence-based consensus meeting was held with urologists, a pharmacist and a cardiologist to perform a structured benefit-risk analysis of reclassifying tadalafil, a phosphodiesterase type 5 (PDE5) inhibitor for treatment of erectile dysfunction (ED),
Kurt Miller +5 more
doaj +1 more source
Cardiovascular Effects of Phosphodiesterase Type 5 Inhibitors
The Journal of Sexual Medicine, 2009 ABSTRACT Introduction Phosphodiesterase type 5 (PDE5) inhibitors are widely used as first-line therapy for erectile dysfunction (ED). Their efficacy and safety combined with an increasing understanding of cyclic guanosine monophosphate (cGMP)-regulated mechanisms have triggered a number of attempts to
Charalambos, Vlachopoulos +3 more
openaire +4 more sources
A review of phosphodiesterase type 5 inhibitors [PDF]
South African Family Practice, 2014 Currently, three phosphodiesterase type 5 (PDE5) inhibitors are available for clinical use in South Africa; sildenafil, vardenafil and tadalafil. The PDE inhibitors are used in males to treat erectile dysfunction. However, sildenafil is also registered for use in the treatment of pulmonary hypertension.
N. Schellack, A. Agoro
openaire +3 more sources